J Ocul Pharm Ther 2023;39:66171
Additionally, HSDD is associated with broader health concerns like depression, sleep disturbances, and lowered life quality, with research showing women with HSDD report 20-30% higher distress levels.[5][8] It's a cycle: low desire leads to avoidance, which reinforces the problem, underscoring why addressing it early is key
GLP-1 therapies influence pathways tied to addiction and reward, according to the Endocrine Society A randomized clinical trial published in JAMA Psychiatry found semaglutide reduced alcohol cravings and consumption Users commonly report: Reduced desire to drink Feeling full faster when drinking Less reward from alcohol The data: early, but directionally consistent While long-term industry sales data is still developing, the early signals from clinical studies, observational research, and population polling all point in the same direction: GLP-1 use is associated with lower alcohol consumption for at least some users
doi: 10.1007/s10482-016-0737-y 71 JoshiS.McMackenM.Kalantar-ZadehK
doi: 10.1038/s41423-024-01232-z 77 HaoZ-NTanX-PZhangQLiJXiaRMaZ